Filter By Category
Archives
Share on -
AMOSTOMIG
Generic Name: AMOSTOMIG
ABSTRACT -
Amostomig is an investigational bispecific antibody designed to target CD47 and PD-L1 (CD274). By combining blockade of the CD47 “do not eat me” signal with PD-L1 checkpoint inhibition, it is being explored for antitumour immune activation in solid tumours. A small-molecule skeletal formula is not applicable; the representation above is a bispecific antibody schematic.
DOSAGE -
Dosage should be determined only by a qualified oncology professional.
No approved standard dosing regimen is established for routine clinical use.
Administration should follow an authorised clinical-trial protocol with infusion monitoring.
Dose modifications depend on infusion reactions, immune-related toxicities, blood counts, organ function, and tumour response.
SIDE EFFECTS–
- Possible side effects include:
- Infusion-related reactions
- Fatigue
- Fever or chills
- Nausea
- Rash or pruritus
- Anaemia
- Thrombocytopenia
- Liver enzyme abnormalities
- Immune-related inflammation such as pneumonitis, colitis, hepatitis, or endocrinopathy
- Infections or tumour-related complications
ALLRGIC REACTIONS–
- Hypersensitivity to amostomig or excipients may occur.
- Symptoms may include urticaria, angioedema, dyspnoea, hypotension, fever, rigors, or anaphylaxis.
- Important: Infusion should occur where emergency treatment is available.
DRUG INTERACTIONS–
- CYP-mediated interactions are not expected.
- Use caution with corticosteroids, immunosuppressants, other checkpoint inhibitors, anti-CD47 agents, cytotoxic chemotherapy, or radiotherapy.
- Live vaccines should generally be avoided during immune-modulating therapy.
- Patients should inform oncology providers about all medicines and supplements.
PREAUTIONS–
- Baseline and periodic blood counts, liver function, renal function, and immune-toxicity assessments are needed.
- Monitor for anaemia and thrombocytopenia due to CD47-pathway effects.
- Use caution in patients with active autoimmune disease, uncontrolled infection, or organ transplant history.
- Pregnancy must be avoided unless a specialist determines benefit outweighs risk.
WARNINGS –
- Amostomig is investigational and not approved for general clinical use.
- Immune-related adverse events can be severe, delayed, or life-threatening.
- Severe infusion reactions require interruption and urgent treatment.
- Keep out of reach of children and use only under oncology supervision.
Share on -
. Developed by